ERBB2 and breast cancer: (16), using breast cancer cell lines, has demonstrated how luminal A and B cell lines are distinguished from one another, while HER2-positive lines are grouped as a single subtype to support studies on tissue subtyping and drug response experiments targeting ER and/or HER2.